Gadolinium and nephrogenic systemic fibrosis: time to tighten practice

Iosif A Mendichovszky, Stephen D Marks, Clare M Simcock, Oystein E Olsen, Iosif A Mendichovszky, Stephen D Marks, Clare M Simcock, Oystein E Olsen

Abstract

Nephrogenic systemic fibrosis (NSF) is a relatively new entity, first described in 1997. Few cases have been reported, but the disease has high morbidity and mortality. To date it has been seen exclusively in patients with renal dysfunction. There is an emerging link with intravenous injection of gadolinium contrast agents, which has been suggested as a main triggering factor, with a lag time of days to weeks. Risk factors include the severity of renal impairment, major surgery, vascular events and other proinflammatory conditions. There is no reason to believe that children have an altered risk compared to the adult population. It is important that the paediatric radiologist acknowledges emerging information on NSF but at the same time considers the risk:benefit ratio prior to embarking on alternative investigations, as children with chronic kidney disease require high-quality diagnostic imaging.

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(00)02694-5', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(00)02694-5'}, {'type': 'PubMed', 'value': '11041404', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/11041404/'}]}
    2. Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000–1001
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/archderm.139.7.903', 'is_inner': False, 'url': 'https://doi.org/10.1001/archderm.139.7.903'}, {'type': 'PubMed', 'value': '12873886', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12873886/'}]}
    2. Ting WW, Stone MS, Madison KC et al (2003) Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139:903–906
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/art.20362', 'is_inner': False, 'url': 'https://doi.org/10.1002/art.20362'}, {'type': 'PubMed', 'value': '15334482', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15334482/'}]}
    2. Jimenez SA, Artlett CM, Sandorfi N et al (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50:2660–2666
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.jaad.2005.04.024', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.jaad.2005.04.024'}, {'type': 'PubMed', 'value': '16427988', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16427988/'}]}
    2. Kucher C, Steere J, Elenitsas R et al (2006) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 54:S31–S34
    1. Cowper SE (2001–2007) Nephrogenic Fibrosing Dermopathy (NFD/NSF Website). . Cited 20 September 2007
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/00002281-200311000-00017', 'is_inner': False, 'url': 'https://doi.org/10.1097/00002281-200311000-00017'}, {'type': 'PubMed', 'value': '14569211', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/14569211/'}]}
    2. Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785–790
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1067/mjd.2003.78', 'is_inner': False, 'url': 'https://doi.org/10.1067/mjd.2003.78'}, {'type': 'PubMed', 'value': '12522371', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12522371/'}]}
    2. Mackay-Wiggan JM, Cohen DJ, Hardy MA et al (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48:55–60
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0002-9343(03)00085-8', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0002-9343(03)00085-8'}, {'type': 'PubMed', 'value': '12753880', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12753880/'}]}
    2. Swartz RD, Crofford LJ, Phan SH et al (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114:563–572
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1053/j.ajkd.2005.08.008', 'is_inner': False, 'url': 'https://doi.org/10.1053/j.ajkd.2005.08.008'}, {'type': 'PubMed', 'value': '16183434', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16183434/'}]}
    2. Cowper SE (2005) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46:763–765
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '16454565', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16454565/'}]}
    2. Gibson SE, Farver CF, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130:209–212
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.0303-6987.2005.00415.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.0303-6987.2005.00415.x'}, {'type': 'PubMed', 'value': '16176298', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16176298/'}]}
    2. Neudecker BA, Stern R, Mark LA et al (2005) Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol 32:612–615
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '17227116', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17227116/'}]}
    2. Solomon GJ, Wu E, Rosen PP (2007) Nephrogenic systemic fibrosis mimicking inflammatory breast carcinoma. Arch Pathol Lab Med 131:145–148
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1191/0961203304lu1069cr', 'is_inner': False, 'url': 'https://doi.org/10.1191/0961203304lu1069cr'}, {'type': 'PubMed', 'value': '15462493', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15462493/'}]}
    2. Obermoser G, Emberger M, Wieser M et al (2004) Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus 13:609–612
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1600-6143.2006.01420.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1600-6143.2006.01420.x'}, {'type': 'PubMed', 'value': '16780542', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16780542/'}]}
    2. Maloo M, Abt P, Kashyap R et al (2006) Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 6:2212–2217
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/00000372-200308000-00017', 'is_inner': False, 'url': 'https://doi.org/10.1097/00000372-200308000-00017'}, {'type': 'PubMed', 'value': '12876500', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12876500/'}]}
    2. Cowper SE, Bucala R (2003) Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25:358
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s11926-006-0055-x', 'is_inner': False, 'url': 'https://doi.org/10.1007/s11926-006-0055-x'}, {'type': 'PubMed', 'value': '16569374', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16569374/'}]}
    2. Quan TE, Cowper SE, Bucala R (2006) The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 8:145–150
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1159/000077321', 'is_inner': False, 'url': 'https://doi.org/10.1159/000077321'}, {'type': 'PubMed', 'value': '15118390', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15118390/'}]}
    2. Lauchli S, Zortea-Caflisch C, Nestle FO et al (2004) Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 208:278–280
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1365-2133.2005.06434.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1365-2133.2005.06434.x'}, {'type': 'PubMed', 'value': '15787823', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15787823/'}]}
    2. Gilliet M, Cozzio A, Burg G et al (2005) Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152:531–536
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/00000372-200306000-00004', 'is_inner': False, 'url': 'https://doi.org/10.1097/00000372-200306000-00004'}, {'type': 'PubMed', 'value': '12775982', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12775982/'}]}
    2. Baron PW, Cantos K, Hillebrand DJ et al (2003) Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25:204–209
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/archderm.140.11.1322', 'is_inner': False, 'url': 'https://doi.org/10.1001/archderm.140.11.1322'}, {'type': 'PubMed', 'value': '15545539', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15545539/'}]}
    2. Kafi R, Fisher GJ, Quan T et al (2004) UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 140:1322–1324
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1365-2133.2003.05795.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1365-2133.2003.05795.x'}, {'type': 'PubMed', 'value': '15030351', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/15030351/'}]}
    2. Chung HJ, Chung KY (2004) Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 150:596–597
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1093/ndt/gfk062', 'is_inner': False, 'url': 'https://doi.org/10.1093/ndt/gfk062'}, {'type': 'PubMed', 'value': '16431890', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16431890/'}]}
    2. Grobner T (2006) Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1681/ASN.2006060601', 'is_inner': False, 'url': 'https://doi.org/10.1681/asn.2006060601'}, {'type': 'PubMed', 'value': '16885403', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16885403/'}]}
    2. Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.jaad.2006.10.047', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.jaad.2006.10.047'}, {'type': 'PubMed', 'value': '17097388', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17097388/'}]}
    2. High WA, Ayers RA, Chandler J et al (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21–26
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.jaad.2006.10.048', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.jaad.2006.10.048'}, {'type': 'PubMed', 'value': '17109993', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17109993/'}]}
    2. Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27–30
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1148/radiol.2431062144', 'is_inner': False, 'url': 'https://doi.org/10.1148/radiol.2431062144'}, {'type': 'PubMed', 'value': '17267695', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17267695/'}]}
    2. Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148–157
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/01.rli.0000253505.88945.d5', 'is_inner': False, 'url': 'https://doi.org/10.1097/01.rli.0000253505.88945.d5'}, {'type': 'PubMed', 'value': '17220732', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17220732/'}]}
    2. Khurana A, Runge VM, Narayanan M et al (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42:139–145
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2214/AJR.06.1094', 'is_inner': False, 'url': 'https://doi.org/10.2214/ajr.06.1094'}, {'type': 'PubMed', 'value': '17242272', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17242272/'}]}
    2. Broome DR, Girguis MS, Baron PW et al (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 188:586–592
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1148/radiol.2423061640', 'is_inner': False, 'url': 'https://doi.org/10.1148/radiol.2423061640'}, {'type': 'PubMed', 'value': '17213364', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17213364/'}]}
    2. Kuo PH, Kanal E, Abu-Alfa AK et al (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647–649
    1. GE Healthcare (2007) Omniscan safety update. . Cited 20 September 2007
    1. Bayer Healthcare Pharmaceuticals (2007) Magnevist labeling update, May 23, 2007. . Cited 20 September 2007
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00330-007-0663-5', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00330-007-0663-5'}, {'type': 'PubMed', 'value': '17458550', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17458550/'}]}
    2. Leiner T, Herborn CU, Goyen M (2007) Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 17:1921–1923
    1. Collidge TA, Thomson PC, Mark PB et al (2007)Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.Radiology. DOI 2451070353
    1. Marckmann P, Skov L, Rossen K et al (2007) Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. DOI 10.1093/ndt/gfm261
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S1076-6332(98)80191-8', 'is_inner': False, 'url': 'https://doi.org/10.1016/s1076-6332(98)80191-8'}, {'type': 'PubMed', 'value': '9653466', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/9653466/'}]}
    2. Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491–502
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1023/A:1009225911668', 'is_inner': False, 'url': 'https://doi.org/10.1023/a:1009225911668'}, {'type': 'PubMed', 'value': '9542065', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/9542065/'}]}
    2. Idee JM, Berthommier C, Goulas V et al (1998) Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals 11:113–123
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/jmri.1880080328', 'is_inner': False, 'url': 'https://doi.org/10.1002/jmri.1880080328'}, {'type': 'PubMed', 'value': '9626889', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/9626889/'}]}
    2. Corot C, Idee JM, Hentsch AM et al (1998) Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. J Magn Reson Imaging 8:695–702
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '8900215', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/8900215/'}]}
    2. Behra-Miellet J, Gressier B, Brunet C et al (1996) Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. Methods Find Exp Clin Pharmacol 18:437–442
    1. None
    2. Green RW, Krestin GP (2006) Non-tissue specific extra cellular MR contrast media. In: Thomsen HS (ed) Contrast media: safety issues and ESUR guidelines. Springer, Berlin, pp 107–112
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1111/j.1472-8206.2006.00447.x', 'is_inner': False, 'url': 'https://doi.org/10.1111/j.1472-8206.2006.00447.x'}, {'type': 'PubMed', 'value': '17109649', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17109649/'}]}
    2. Idee JM, Port M, Raynal I et al (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '8486501', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/8486501/'}]}
    2. Harpur ES, Worah D, Hals PA et al (1993) Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 28 [Suppl 1]:S28–S43
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '9210255', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/9210255/'}]}
    2. Spencer AJ, Wilson SA, Batchelor J et al (1997) Gadolinium chloride toxicity in the rat. Toxicol Pathol 25:245–255
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.semarthrit.2005.08.002', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.semarthrit.2005.08.002'}, {'type': 'PMC', 'value': 'PMC1434722', 'is_inner': False, 'url': 'http://www.ncbi.nlm.nih.gov/pmc/articles/pmc1434722/'}, {'type': 'PubMed', 'value': '16461069', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16461069/'}]}
    2. Mendoza FA, Artlett CM, Sandorfi N et al (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238–249
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '6144674', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/6144674/'}]}
    2. Itoh N, Kawakita M (1984) Characterization of Gd3+ and Tb3+ binding sites on Ca2+,Mg2+–adenosine triphosphatase of sarcoplasmic reticulum. J Biochem (Tokyo) 95:661–669
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC2041618', 'is_inner': False, 'url': 'http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2041618/'}, {'type': 'PubMed', 'value': '7459256', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/7459256/'}]}
    2. Husztik E, Lazar G, Parducz A (1980) Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br J Exp Pathol 61:624–630
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/00004424-199610000-00003', 'is_inner': False, 'url': 'https://doi.org/10.1097/00004424-199610000-00003'}, {'type': 'PubMed', 'value': '8889650', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/8889650/'}]}
    2. Puttagunta NR, Gibby WA, Puttagunta VL (1996) Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest Radiol 31:619–624
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0730-725X(03)00081-X', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0730-725x(03)00081-x'}, {'type': 'PubMed', 'value': '12878264', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/12878264/'}]}
    2. Bartolini ME, Pekar J, Chettle DR et al (2003) An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis. Magn Reson Imaging 21:541–544
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/0003-9861(77)90511-2', 'is_inner': False, 'url': 'https://doi.org/10.1016/0003-9861(77)90511-2'}, {'type': 'PubMed', 'value': '141909', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/141909/'}]}
    2. Krasnow N (1977) Lanthanide binding to cardiac and skeletal muscle microsomes. Effects of adenosine triphosphate, cations, and ionophores. Arch Biochem Biophys 181:322–330
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1085/jgp.95.4.679', 'is_inner': False, 'url': 'https://doi.org/10.1085/jgp.95.4.679'}, {'type': 'PMC', 'value': 'PMC2216337', 'is_inner': False, 'url': 'http://www.ncbi.nlm.nih.gov/pmc/articles/pmc2216337/'}, {'type': 'PubMed', 'value': '2159974', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/2159974/'}]}
    2. Lansman JB (1990) Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit. J Gen Physiol 95:679–696
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1067/S0022-3476(03)00538-9', 'is_inner': False, 'url': 'https://doi.org/10.1067/s0022-3476(03)00538-9'}, {'type': 'PubMed', 'value': '14615747', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/14615747/'}]}
    2. Jan F, Segal JM, Dyer J et al (2003) Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143:678–681
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00467-003-1380-1', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00467-003-1380-1'}, {'type': 'PubMed', 'value': '14872332', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/14872332/'}]}
    2. Jain SM, Wesson S, Hassanein A et al (2004) Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 19:467–470
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00467-006-0384-z', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00467-006-0384-z'}, {'type': 'PubMed', 'value': '17180360', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/17180360/'}]}
    2. Dharnidharka VR, Wesson SK, Fennell RS (2007) Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 22:1395
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.jaad.2006.01.023', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.jaad.2006.01.023'}, {'type': 'PubMed', 'value': '16635686', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16635686/'}]}
    2. DiCarlo JB, Gupta EA, Solomon AR (2006) A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy. J Am Acad Dermatol 54:914–916
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s00467-006-0174-7', 'is_inner': False, 'url': 'https://doi.org/10.1007/s00467-006-0174-7'}, {'type': 'PubMed', 'value': '16821025', 'is_inner': True, 'url': 'http://pubmed.ncbi.nlm.nih.gov/16821025/'}]}
    2. Auron A, Shao L, Warady BA (2006) Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 21:1307–1311

Source: PubMed

3
Abonnieren